[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 3944 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  2d Session
                                S. 3944

  To amend the Public Health Service Act to reauthorize the WISEWOMAN 
                                program.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                           February 26, 2026

 Ms. Alsobrooks (for herself and Mrs. Britt) introduced the following 
  bill; which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
  To amend the Public Health Service Act to reauthorize the WISEWOMAN 
                                program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Women's Heart Health Expansion Act 
of 2026''.

SEC. 2. REAUTHORIZATION OF WISEWOMAN PROGRAM.

    Section 1509 of the Public Health Service Act (42 U.S.C. 300n-4a) 
is amended to read as follows:

``SEC. 1509. SUPPLEMENTAL GRANTS FOR ADDITIONAL PREVENTIVE HEALTH 
              SERVICES.

    ``(a) Screening and Referral Projects.--The Secretary, acting 
through the Director of the Centers for Disease Control and Prevention, 
may award supplemental grants to recipients of grants under section 
1501 to carry out projects for the purposes of--
            ``(1) providing preventive health services in addition to 
        the services authorized in such section, including--
                    ``(A) screenings regarding blood pressure, 
                cholesterol, obesity, and other relevant risk factors; 
                and
                    ``(B) evidence-based health education offered by a 
                qualified provider to improve a measurable health 
                outcome, such as blood pressure, cholesterol, diabetes, 
                or obesity;
            ``(2) providing appropriate referrals for medical treatment 
        of women receiving services pursuant to paragraph (1) and 
        ensuring, to the extent practicable, the provision of 
        appropriate follow-up services; and
            ``(3) evaluating activities conducted under paragraphs (1) 
        and (2) through appropriate surveillance or program-monitoring 
        activities and reporting to the Secretary on such activities.
    ``(b) Eligibility for Services.--Women eligible for services 
pursuant to a grant under subsection (a) shall include--
            ``(1) women eligible for services pursuant to a grant made 
        under section 1501; and
            ``(2) other women who are high-risk and meet such 
        eligibility criteria as the Secretary may specify.
    ``(c) Authorized Providers.--Health services provided pursuant to a 
grant under subsection (a) shall be provided by--
            ``(1) an entity screening women for breast and cervical 
        cancer pursuant to a grant under section 1501; or
            ``(2) other health care entities, as the Secretary 
        determines.
    ``(d) Funding.--To carry out this section, there is authorized to 
be appropriated $250,000,000 for the period of fiscal years 2027 
through 2031.''.

SEC. 3. GAO STUDY.

    Not later than September 30, 2027, the Comptroller General of the 
United States shall report to the Committee on Health, Education, 
Labor, and Pensions of the Senate and the Committee on Energy and 
Commerce of the House of Representatives on the work of the Well-
Integrated Screening and Evaluation for Women Across the Nation 
Program, including--
            (1) an estimate of the number of individuals eligible for 
        services provided under such program;
            (2) a summary of trends in the number of individuals served 
        through such program;
            (3) an assessment of any factors that may be driving the 
        trends identified under paragraph (2), including any barriers 
        to accessing cardiovascular health screenings provided by such 
        program; and
            (4) an analysis of the cost-effectiveness of such program 
        with respect to patient outcomes, such as blood pressure, 
        cholesterol, diabetes, or obesity.
                                 <all>